Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

Article Abstract:

A phase 3, randomized, open-label study compared lapatinib plus capecitabine with capecitabine alone in women with progressive, human epidermal growth factor receptor type 2-positive (HER2-positive), locally advanced or metastatic breast cancer who were previously treated with a minimum of an anthracycline, a taxane, and trastuzumab. Results provide support for the use of lapatinib and capecitabine in women with progression of HER2-positive breast cancer after treatment with trastuzumab.

Author: Chan, Stephen, Berger, Mark, Chan, Arlene, Pienkowski, Tadeusz, Geyer, Charles E., Forster, John, Lindquist, Deborah, Romieu, C. Gilles, Jagiello-Gruszfeld, Agnieszka, Crown, John, Kaufman, Bella, Skarlos, Dimosthenis, Campone, Mario, Davidson, Neville
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
Dosage and administration, Trastuzumab, Clinical report, Lapatinib (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Aromatase inhibitors in breast cancer

Article Abstract:

The clinical uses, benefits, and adverse effects of aromatase inhibitors for treating breast cancer are reviewed. This group of drugs inhibits the enzyme aromatase, which synthesizes estrogen from its precursor. This blocks the formation of estrogen, which stimulates the formation of breast cancer in some women. Some of the aromatase inhibitors are more effective than tamoxifen.

Author: Smith, Ian E., Dowsett, Mitch
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
Evaluation, Aromatase inhibitors

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

Article Abstract:

A comparison of letrozole with tamoxifen as adjuvant for steroid-hormone-receptor-positive breast cancer in postmenopausal women is presented. In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites.

Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
England, Health aspects, Usage, Comparative analysis, Postmenopausal women, Tamoxifen, Letrozole

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy, Breast cancer
Similar abstracts:
  • Abstracts: Cerebral salt wasting in children: the need for recognition and treatment. Abdominal symptoms as presentation of hypertensive crisis
  • Abstracts: Dentists' attitudes toward the treatment of HIV-positive patients. Managing the care of patients infected with bloodborne diseases
  • Abstracts: Chronic pain in wounds: A report on 11 case studies. Use of oxygen therapy
  • Abstracts: The nursing of a patient following lung volume reduction surgery. Procedure for the assessment of lung function with spirometry
  • Abstracts: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.